Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cogent Biosciences (COGT) EBITDA (2017 - 2026)

Cogent Biosciences' EBITDA history spans 10 years, with the latest figure at -$98.1 million for Q1 2026.

  • Quarterly EBITDA fell 35.77% to -$98.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$354.9 million through Mar 2026, down 31.78% year-over-year, with the annual reading at -$329.0 million for FY2025, 28.7% down from the prior year.
  • EBITDA came in at -$98.1 million for Q1 2026, up from -$102.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$30.6 million in Q1 2022 to a low of -$102.3 million in Q4 2025.
  • The 5-year median for EBITDA is -$58.6 million (2024), against an average of -$59.7 million.
  • Year-over-year, EBITDA crashed 161.92% in 2022 and then dropped 16.09% in 2025.
  • Cogent Biosciences' EBITDA stood at -$39.6 million in 2022, then tumbled by 36.37% to -$53.9 million in 2023, then decreased by 26.75% to -$68.4 million in 2024, then tumbled by 49.68% to -$102.3 million in 2025, then increased by 4.13% to -$98.1 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's EBITDA are -$98.1 million (Q1 2026), -$102.3 million (Q4 2025), and -$80.7 million (Q3 2025).